Intellectual Property,
Administrative/Regulatory
Oct. 24, 2013
Washington stirs as India undermines patents
India's approach to pharmaceutical patents is garnering increased attention in Washington, with recent high-level pressure on the Indian government to do more to protect intellectual property.
David Weller
Partner
WilmerHale
David is former deputy assistant U.S. trade representative for China. He is a partner in the Washington, D.C. office of the WilmerHale law firm in its Regulatory and Government Affairs Department and a member of the International Trade, Investment and Market Access Practice Group. He represents clients regarding trade and regulatory impediments to accessing foreign markets in international dispute settlement proceedings and on trade policy issues.
India's approach to pharmaceutical patents is garnering increased attention in Washington, with recent high-level pressure on the Indian government to do more to protect intellectual property.
In particular, India's recent endorsement of compulsory licenses as a tool to address drug pricing has caused widespread concern in the biopharma sector, as well as in other sectors that rely on strong patent protection. How India responds to these concerns, and what actions the U.S. ...For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In